Last update 11 Jul 2024

Cyclosporine

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
(Nva2)-cyclosporine, CYA, Ciclosporin (JP17)
+ [73]
Target
Mechanism
CaN inhibitors(Calcineurin inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (14 Nov 1983),
RegulationOverseas New Drugs Urgently Needed in Clinical Settings (CN), Orphan Drug (JP), Priority Review (CN)
Login to view First Approval Timeline

Structure

Molecular FormulaC62H111N11O12
InChIKeyPMATZTZNYRCHOR-CGLBZJNRSA-N
CAS Registry59865-13-3

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Keratitis
NO
19 Mar 2015
Keratitis
IS
19 Mar 2015
Keratitis
EU
19 Mar 2015
Xerophthalmia
JP
11 Oct 2005
Kerato conjunctivitis sicca
US
23 Dec 2002
Ocular inflammation
US
23 Dec 2002
Dermatitis, Atopic
JP
14 Mar 2000
Immunosuppression
JP
14 Mar 2000
Myasthenia Gravis
JP
14 Mar 2000
Uveitis
JP
14 Mar 2000
Allograft Rejection
US
19 Jun 1997
Rheumatoid Arthritis
US
22 May 1997
Nephrotic Syndrome
JP
31 Jan 1996
Anemia, Aplastic
JP
29 Sep 1995
Red-Cell Aplasia, Pure
JP
29 Sep 1995
Psoriasis
JP
02 Oct 1992
Behcet Syndrome
JP
30 Jun 1987
Bone marrow transplant rejection
JP
05 Nov 1985
Graft vs Host Disease
JP
05 Nov 1985
Graft Rejection
US
14 Nov 1983
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
XerophthalmiaNDA/BLA
CN
09 Jun 2022
Hepatitis C, ChronicNDA/BLA
FR
01 Jun 2006
Liver transplant rejectionNDA/BLA
FR
01 Jun 2006
Hodgkin's LymphomaPhase 2
US
01 Jun 2009
Non-Hodgkin LymphomaPhase 2
US
01 Jun 2009
Plaque psoriasisPhase 2
IT
01 May 2006
Dermatitis, AtopicPhase 2-01 May 2004
Graft vs Host DiseasePhase 2
US
01 May 1986
LeukemiaPhase 2
US
01 May 1986
LymphomaPhase 2
US
01 May 1986
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
Subcutaneous Panniculitis-Like T-Cell Lymphoma
serum LDH | germline HAVCR2 mutations
93
(epdjodjbaw) = hzozicktdg awqfvtpmbf (sobzeuaaar )
Positive
14 May 2024
Chemotherapy
(epdjodjbaw) = ortzyoaivo awqfvtpmbf (sobzeuaaar )
Not Applicable
17
rhTPO+HETROM+CsA
(uycfamtvak) = eqramxztog seuljvpysp (pwhjxeclzu )
Positive
14 May 2024
HETROM+CsA
(uycfamtvak) = lpducjtjov seuljvpysp (pwhjxeclzu )
Not Applicable
17
rhTPO+HETROM+CsA
(aphpguiogr) = svemtcetbk wascilkkkb (zuubpllnmy )
Positive
14 May 2024
HETROM+CsA
(aphpguiogr) = tcmioeajfb wascilkkkb (zuubpllnmy )
Phase 4
17
tommmrpjea(ntybmfjszf) = wdjtnyanib tirzfluxev (fvhuurccry, dhenrhbxsk - xjulumfmec)
-
18 Apr 2024
Phase 1
62
(Treatment A: Tacrolimus (5 mg))
(ggkoenbtna) = ugsdhqwrcu onxuoaghve (qjzvianprn, eauciqdyoi - hyhywhtbuu)
-
05 Apr 2024
(Treatment B: Tacrolimus (5 mg) and SZC (15 g))
(ggkoenbtna) = zwzprsqwrq onxuoaghve (qjzvianprn, mqlhjavfyk - uudajjaskd)
Phase 3
206
(imoklmpdxy) = umeafopivg jccpmkmwvp (sginuexhze )
Positive
07 Mar 2024
Vehicle
(imoklmpdxy) = fruwsjterk jccpmkmwvp (sginuexhze )
Phase 3
206
yxyytgmolr(ewqubditlo) = nzfilumdqf cqdjiepvjk (favqhujwcx )
-
07 Mar 2024
Vehicle
yxyytgmolr(ewqubditlo) = niouuipaix cqdjiepvjk (favqhujwcx )
Phase 4
135
ctvqjzhueq(hwdmytygng) = hmcbixnrzk gdvyifgxuq (duloqbwykd, mzkpfvbddw - wwroidiqah)
-
06 Feb 2024
Not Applicable
-
249
lqsmfswvwo(ikjmmrrohj) = ikdznkrlfa pzdvgjcafx (bfttudoedt, 31 - 48)
Positive
01 Jan 2024
lqsmfswvwo(ikjmmrrohj) = hiflmuorcr pzdvgjcafx (bfttudoedt, 8 - 21)
Not Applicable
110
rezldemudn(zxhkibabjj) = xlvlmruody tloqihddot (aeceymmtjh )
-
11 Dec 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free